Email This Article
Headlines & Perspectives
Icahn, Byetta Sales Boost Amylin (Update)
By
Elizabeth Trotta
11/17/08 - 05:40 PM EST
The biotech's shares rise on news of an increased bet by investor Carl Icahn and an uptick in its diabetes drug's prescription data.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,464.40 | 1,110.63 | 2,176.05 | 32.79 |
Oil *
77.05
|
|
UP
30.69
|
UP
4.98
|
UP
6.87
|
DOWN
0.38
|
10 Yr
3.28%
SPDR Gold
116.62
|
|
+0.29%
|
+0.45%
|
+0.32%
|
-1.15%
|
Data delayed 20 minutes |


Connect with TheStreet